Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-16 of 16 for your search:
Start Over
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Vaccine Therapy in Treating Patients With Prostate Cancer Previously Treated With Surgery or Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 06-070, NCI-2011-01874, NCT00970203
Prostatic Acid Phosphatase-Sargramostim Fusion Protein or Sargramostim in Treating Patients with Non-Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO 08801, NCI-2011-00965, H-2008-0073, NCT01341652
Sipuleucel-T with or without Indoximod in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011LS109, NCI-2012-00923, 1202M10704, NCT01560923
Sipuleucel-T with or without DNA Vaccine Therapy in Treating Patients with Hormone-Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO11816, NCI-2012-02026, NCT01706458
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12367, NCI-2013-00542, 097472, NCT01807065
Enzalutamide with or without Vaccine Therapy in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0146, NCI-2013-01565, 1301-1204, 130146, P121106, RD-13-I-11, NCT01867333
Enzalutamide with or without Vaccine Therapy in Treating Patients with Non-metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0153, NCI-2013-01570, 1301-1205, 130153, P121105, RD-13-I-12, NCT01875250
Vaccine Therapy in Treating Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0112, NCI-2014-02498, 1401-1286, P131384, RD-14-I-08, NCT02153918
Sipuleucel-T with or without Tasquinimod in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 250813, NCI-2014-01184, NCT02159950
Immediate or Delayed Ipilimumab after Sipuleucel-T Treatment in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12557, NCI-2014-00318, 079730, CC#12557, NCT01804465
Dendritic Cell Vaccine Therapy in Treating Patients with Stage D0 Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0075, NCI-2015-00171, 150075, 15-C-0000, 15-C-xxxx, NCT02362451
Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0016, NCI-2013-01564, 130016, P12990, NCT01730118
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BP-PC-002, NCI-2013-01266, NCT01823978
Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: O11-10678, NCI-2014-01906, Department of Defense, NCT02058680
Radiation Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 223912, NCI-2013-00633, NCT01833208
Start Over